|
Reference #:
2006-115
Inventors/Contributors
Todd E. Golde M.D., Yona R. Levites Ph.D., Karen R. Jansen-West B.A., Pritam Das Ph.D.
Description
Accumulation of Abeta in the brain of patients who suffer from Alzheimer’s disease (AD) triggers a complex series of events that eventually result in neuronal dysfunction and death. Selective targeting of Abeta using high affinity binding agents holds great promise as a potential way to treat or prevent AD. In order to avoid complications associated with immune effector functions of antibodies we have generated novel recombinant single chain autobodies that selectively bind either Abeta40 or Abeta 42. Delivery of these to the brain of Abeta depositing mice significantly retards amyloid deposition. Nucleic acid and protein sequences of these scFVs are disclosed as well as methods for treatment of AD with these anti-abeta scFV are described.
Patent Status
Pending |
|
Contact
Susan L. Stoddard, Ph.D., Licensing Manager
sstoddard@mayo.edu
|
|
Mayo Foundation for Medical Education and Research
Office of Technology Commercialization
Centerplace 4
200 First Street SW
Rochester, MN 55905
|
Phone: (507) 284-1222
Fax: (507) 284-5410
|
|
|
